Avocadosoybean Unsaponifiables

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: joints inflammation pain

Research Overview

Research on avocado–soybean unsaponifiables (ASU) has been studied primarily in the context of symptomatic management of osteoarthritis (OA), with the strongest focus on knee and hip OA. The most commonly evaluated outcomes in randomized, placebo-controlled trials include patient-reported pain (often via visual analog scale, VAS), functional status and symptom severity (e.g., Lequesne index), and in some studies structural measures such as joint space width (JSW). Evidence syntheses to date have therefore concentrated on whether oral ASU improves OA symptoms and whether it is well tolerated compared with placebo.

The strongest evidence supports a modest symptomatic benefit of ASU in knee OA. Meta-analytic findings indicate statistically significant reductions in pain (VAS) and improvements in Lequesne index in knee OA populations, while similar benefits have not been consistently demonstrated in hip OA. Safety data from pooled randomized trials suggest ASU has an adverse-event profile comparable to placebo, with no clear signal of increased harms in the studied durations and populations. However, heterogeneity across trials is substantial for some outcomes (notably pain), which reduces certainty about the magnitude and consistency of effect.

Key gaps include the need for additional high-quality, adequately powered trials in hip OA to clarify whether the apparent lack of benefit reflects true inefficacy or limitations of existing evidence. More research is also needed to address sources of heterogeneity (e.g., differences in ASU formulation/dose, baseline disease severity, concomitant analgesic use, and trial duration), and to better establish clinically meaningful effect sizes. Finally, longer-term studies with standardized structural endpoints (e.g., JSW or modern imaging) and rigorous assessment of disease-modifying potential would help determine whether ASU influences OA progression beyond short-term symptom relief.

1. What conditions has Avocadosoybean Unsaponifiables been studied for?

  • Osteoarthritis (OA) of the knee and hip, specifically for symptom outcomes (pain and function) and, in some trials, structural outcomes (joint space width).

2. Does it work in treating those conditions? Summarize the evidence.

  • Knee osteoarthritis: Evidence from the cited systematic review/meta-analysis of randomized placebo-controlled trials suggests ASU improves symptoms.

    • Pain (VAS): In knee OA subanalysis, ASU reduced pain versus placebo (WMD: -17.36 mm, 95% CI: -25.91 to -8.82; P < .0001), though heterogeneity was high (I2 = 87%).

    • Function/symptoms (Lequesne index): In knee OA subanalysis, ASU improved Lequesne index (WMD: -2.33, 95% CI: -2.88 to -1.78; P < .00001) with low heterogeneity (I2 = 18%).

  • Hip osteoarthritis: The meta-analysis concluded ASU was not significantly effective for hip OA symptoms (i.e., benefits seen in knee OA were not observed in hip OA).

  • Overall OA pain (mixed hip/knee): Across included trials, ASU reduced pain on VAS (WMD: -9.64 mm, 95% CI: -17.43 to -1.84; P = .02), but heterogeneity was very high (I2 = 92%), which lowers confidence in the consistency of the effect.

Key limitation from the abstract: High heterogeneity for pain outcomes (I2 87–92%) suggests results varied substantially across trials (e.g., differences in populations, OA severity, dosing/duration, or study methods).

3. What health benefits does it have?

  • Symptom relief in knee OA: Reduced pain (VAS) and improved OA symptom/function scores (Lequesne index) versus placebo in knee OA subanalysis.

  • Possible overall OA pain reduction: When pooling hip and knee OA trials, ASU showed a modest average reduction in pain versus placebo, though results were inconsistent across studies (high heterogeneity).

  • Structural benefit (joint space width): The abstract indicates trials assessed joint space width (JSW), but it does not report pooled JSW results; therefore, a structural/disease-modifying benefit cannot be concluded from the provided abstract.

4. Does it have any downsides or side effects?

  • Adverse events: In the meta-analysis, adverse events were similar to placebo (relative risk: 1.02, 95% CI: 0.83 to 1.25; P = .88; I2 = 0%), suggesting no detectable increase in overall side effects in the included trials.

  • Downside/uncertainty: Benefits appear condition-specific (supported for knee OA but not hip OA), and pain results show substantial between-study variability (high heterogeneity), which may limit predictability for an individual patient.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • No pharmacogenomic evidence reported: The provided abstract does not mention genetic variants, genotype-stratified responses, or gene–supplement interactions for ASU.

  • Conclusion based on available abstract: There is insufficient evidence from the cited research summary to say ASU is beneficial or harmful for any specific genetic variations.

References

  1. Efficacy and safety of avocado-soybean unsaponifiables for the treatment of hip and knee osteoarthritis: A systematic review and meta-analysis of randomized placebo-controlled trials
    Mario Simental-Mendía, Adriana Sánchez-García, Carlos A Acosta-Olivo, Félix Vilchez-Cavazos, Jorge Osuna-Garate (2019)


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!